Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR168 in Refractory Systemic Sclerosis
NCT07854483Phase 1Not yet recruiting
- Sponsor
- AbelZeta
- Start
- Mar 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR168 in systemic sclerosis (SSc), sponsored by AbelZeta. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 24 months. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
C-CAR168
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07854483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854483.